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To survey the frequency of extra-pulmonary symptoms reported by a sample of 
patients with severe asthma, their contribution to quality of life and relationship to 
treatment pathways.  
Methods 
Consenting patients (N = 100) attending a severe asthma clinic completed 
questionnaire measures of extra-pulmonary symptoms (the General symptom 
Questionnaire, GSQ), pulmonary symptoms (Asthma Control Test, ACT), quality of 
life (the Severe Asthma Questionnaire, SAQ) and health status (EQ-5D-5L). 
Results 
A median of 21 extra-pulmonary symptoms were reported per week. GSQ correlated 
-0.65 with the ACT and 0.69 with the SAQ.  Linear regression showed that both the 
ACT and GSQ were significant predictors of SAQ mean score, p < 0.001. In patients 
not receiving biologics, those with high cumulative OCS exposure (≥1120mg per 
year) had significantly worse scores (p < 0.05) on all questionnaires except the ACT 
and GSQ compared to those with low cumulative OCS exposure.  
 
Discussion 
Extra-pulmonary symptoms were common in this sample of people with severe 
asthma. Extra-pulmonary and pulmonary symptoms contribute equal variance to the 
score of HRQoL, showing that they are equally important contributors to patients’ 
experience of severe asthma. Extra-pulmonary symptoms are often overlooked in 
clinical medicine and in measures of quality of life. Participants receiving biologic 
treatments had lower extra-pulmonary symptoms possibly indicating that biologics 
reduce systemic symptoms more effectively than other treatments. 
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A patient’s health-related quality of life (HRQoL) is determined by a combination of 
symptoms, personality, opportunities and choices (1). Patients with severe asthma 
have pulmonary symptoms, but they also have extra-pulmonary symptoms that arise 
from a variety of causes, such as co-morbidities and side effects of treatments (2).  
These extra-pulmonary symptoms are often neglected in asthma outcome research. 
Commonly used patient reported outcome (PRO) measures such as the Asthma 
Quality of Life Questionnaire (3)  and the St George’s Respiratory Questionnaire (4), 
include pulmonary symptom items along with quality of life items. The impact of 
extra-pulmonary symptoms on quality of life is unknown. 
 
This study has three aims. The first is to establish the frequency of extra-pulmonary 
symptoms in a clinical population of patients attending a severe asthma clinic.  The 
second is to examine the relationship between pulmonary symptoms, extra-
pulmonary symptoms and quality of life to determine the relative contributions of 
pulmonary and extra-pulmonary symptoms to quality of life using a quality of life 
questionnaire specifically developed for severe asthma. The third is to evaluate to 
what extent extra-pulmonary symptoms and other patient reported outcomes 
discriminate between severe asthma patients receiving different treatments i.e. oral 
corticosteroids (OCS) and/or novel biologic agents. 
Methods 
Participants 
Patients aged ≥16 years and attending the Plymouth severe asthma clinic were 
invited to participate as part of a questionnaire validation study (5). All patients were 
diagnosed with severe asthma as defined by the European Respiratory Society 
(ERS) and American Thoracic Society (ATS) guidelines (6), and were excluded if 
they had another condition that could contribute significantly to their respiratory 
symptoms e.g., bronchiectasis, heart failure or COPD. 
Measures  
Asthma specific Health Related Quality of Life: Severe Asthma Questionnaire (SAQ) 
The SAQ is a recently developed questionnaire for patients with severe asthma that 
comprises two patient reported outcome measures, a 16-item questionnaire and a 
global rating scale. All the 16 questions have response options on a 7-point scale 
averaged to produce an SAQ score (scores 1 – 7). The 100-point SAQ-global scale 
measures overall quality of life on a single scale. For both scales high scores 
indicate better HRQoL. The questionnaire was designed to measure asthma specific 
quality of life in people with severe asthma (7, 8). 
Asthma symptoms: Asthma Control Test (ACT) 
The ACT measures asthma control by a combination of respiratory symptoms, 
reliever use and perceived asthma control. It comprises five symptom related items 
and medication items (5 response options per item) totalled to produce an asthma 
control score (9) with a higher score indicating better asthma control. This 
questionnaire was used to measure asthma specific symptoms. 
Extra-pulmonary symptoms: General symptom questionnaire (GSQ).  
The GSQ is a 65 item questionnaire that was designed to measure the symptoms of 
patients with fibromyalgia, irritable bowel syndrome and chronic fatigue syndrome 
(10). The questionnaire assesses the frequency of extra-pulmonary symptoms, such 
as somatic and psychological symptoms, on a 6 point Likert scale (the value scoring 
for each response shown in brackets): “Never or almost never” (1), “Less than 3 or 4 
times per year” (2), “Every month or so” (3), “Every week or so” (4), “More than once 
per week” (5) or “Every day” (6). This questionnaire was used to measure the 
number and frequency of extra-pulmonary symptoms reported by patients.  
The GSQ score was calculated from the mean of all items with a higher score 
indicating poorer health.  The number of weekly non-respiratory symptoms reported 
was calculated by counting the number of items with a score of 4 or more. The 
number of daily non-respiratory symptoms was calculated by counting the number of 
items with a score of 6. See online Supplement for a full list of items.  
Health status: EQ-5D-5L 
This is a 5-item scale scored from 1-5 with a higher score indicating worse health. 
For the purposes of this study the mean score of the five items was used as the 
score for the EQ-5D-5L. In addition to the 5 items, the EQ-5D-5L also includes a 
category rating scale to rate their quality of life on the day of completion. This is 
scored from 0-100 with a higher score indicating better health (EQ5D -VAS) (11). 
Clinic Data 
The following clinic data were obtained: Percent predicted of forced expiratory 
volume in one second (FEV1), Percent predicted of forced expiratory volume 
(FEV1%), treatment step as defined by Global Initiative for Asthma (GINA) (12) and 
Body Mass Index (BMI). Estimated cumulative oral corticosteroid (OCS) dose over 
the previous year was calculated by multiplying the participant’s maintenance steroid 
dose by 365 days, and adding an estimate of OCS use per exacerbation in the 
previous 12 months. Based on British Thoracic Society and GINA guidance, an 
exacerbation was estimated to be treated with prednisolone 40mg/day for 7 days 
which equates to 280mg of prednisolone per exacerbation(12, 13). 
 
Procedure 
After providing written informed consent, clinically stable participants completed the 
questionnaires either at home or during their clinic visit. At the time of completion 
questionnaires were not anonymous but were anonymised prior to analysis. 
Questionnaires were deemed incomplete if 15% or more items were missing.  
Analysis 
Correlations are estimated by using Pearson correlation coefficients. Three linear 
regressions were conducted to calculate the unique variance in SAQ. The first included 
the ACT and GSQ as independent variables, second included only the ACT as an 
independent variable and the third included only the GSQ as an independent variable. 
The difference in the R2 of the second and first regression was calculated to provide the 
unique variance explained by the GSQ. The difference in R2 between the third and first 
regression was calculated to identify the unique variance explained by the ACT. This was 
repeated with the SAQ-Global as the dependent variable.  
 
We used t-tests to compare PROs between selected groups of patients taking different 
medications, groups being selected so as to avoid treatment confounds. Patients were 
allocated to four groups, low or high cumulative OCS (low 0 -1119mg per year, high 
≥1120mg per year) and those receiving or not receiving biologic treatments. The mean 
questionnaire scores for each of these four groups were calculated. Differences in 
questionnaire scores were compared between the following groups: (a) those high on 
OCS and also on biologics versus those high on OCS but not on biologics, and (b) those 
with high cumulative OCS exposure but not on biologics versus those low on OCS but 
not on biologics. The remaining comparisons, c) those with low cumulative OCS on 
biologics versus those with low cumulative OCS but not on biologics, and (d) those on 
biologics with high cumulative OCS versus on biologics with low cumulative OCS 




Data collection was approved by the Plymouth Hospitals NHS Trust and REC/HRA, 
ethical approval number 16/NE/0188, IRAS ID: 207601.  All participants provided 
informed written consent. 
Results 
One hundred patients were recruited from a severe asthma clinic. Of these 28 were 
receiving omalizumab and four were receiving mepolizumab at the time of 
participation. Further characteristics of the sample are shown in Table 1. 
  
Table 1: Demographic information for all participants and those at GINA steps four 
and five. 
 
 All GINA step 4 GINA step 5 
Subjects (n) 100 61 39 
Female 63 38 25 
Age years 51 (16 - 78) 50 (16 - 50) 55 (30 - 79) 
Fev1 (L) 1.9 (0.7- 4.1) 2.1 (0.7 – 4.1) 1.8 (0.7 – 3.4) 
FEV1 (% 
predicted) 
70 (35 - 116) 73 (37 - 116) 65 (35 - 107) 
BMI (kg/m2 ) 31.6 (20.4 – 58.3) 30.4 (20.4 – 58.3) 33.4 (23.1 – 54.7) 
Median ICS dose 
BDP equivalent 
µg day-1 




The mean scores for all questionnaires can be found in Table 2. 




SAQ score 3.96 (3.64-4.27) 
n= 96 
ACT 14.02 (12.76 - 15.28) 
n= 99 




2.18 (1.98 – 2.38) 
n= 96 




54.69 (50.00 – 59.38) 
n= 97 
*A high score indicates poor health. 
 
Frequency of extra-pulmonary symptoms 
The median number of daily extra-pulmonary symptoms reported by participants was 
six and of weekly extra-pulmonary symptoms was 21. Figure 1 provides a 
distribution of the number of extra-pulmonary symptoms reported by patients on a 
weekly and daily basis. Table E1 in the online supplement provides a full list of items 
included in the General Symptom Questionnaire, and the percentages of participants 
experiencing these symptoms weekly or daily.  
 
Figure 1: Frequency distributions of extra-pulmonary symptoms experienced weekly 
and daily (N = 100).  
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Data are presented as correlation coefficient (n). SAQ: Severe Asthma 
Questionnaire; ACT: Asthma Control Test; GSQ: General Symptom Questionnaire, 
VAS: visual analogue scale; BMI: body mass index; FEV1: forced expiratory volume 
in 1 s. *: p<0.05, **: p<0.01. 
# A high score indicates poor health.  
 
Variation of HRQoL explained  
 
Linear regressions were carried out to determine the extent to which the GSQ and 
ACT were predictors of both the SAQ and SAQ-global. 
 
For the SAQ, the combined variance of the ACT and GSQ explained 57% of the 
variation of the SAQ (R2 = 0.57, p < 0.001).  The variation in SAQ explained by the 
ACT alone was 47% (R2 = 0.47, p < 0.001) showing that the unique variance 
attributed to the GSQ was 57 – 47 = 10%.  The variation in SAQ explained by the 
GSQ alone was 48% (R2 = 0.48, p < 0.001) showing that the unique variance 
attributed to the ACT was 57 – 48 = 9%.  The variation in SAQ explained by the 
shared variance of GSQ and ACT was 57 – 10 – 9 = 38%.  
ACT and GSQ explained 50% of the variation of the SAQ-global (R2 = 0.50, p < 
0.001).  The SAQ-global variation explained by the ACT alone was 45% (R2 = 0.45, p 
< 0.001) showing that the unique variation in SAQ-global attributed to the GSQ was 
50 - 45 = 5%.  The SAQ-global variation explained by the GSQ alone was 35% (R2 = 
0.35, p < 0.001) showing that the unique variation in SAQ-global attributed to the 
ACT was 15%.  The SAQ-global variance shared explained by the shared variance 
of GSQ and ACT was 50 – 5 – 15 = 30%. 
These results show that the GSQ and ACT are approximately equal contributors to 
variation for the SAQ, whereas for the SAQ-global, the contribution of the GSQ to the 
variation is less than the contribution of the ACT.  
 
Impact of treatment  
To examine the cross-sectional relationship between treatment and outcomes, 
patients were allocated to four groups, low or high cumulative OCS (low 0 -1119mg 
per year, high ≥1120mg per year) and those receiving or not receiving biologics. The 
mean questionnaire scores for these four groups were calculated (see Table 4).   
In patients receiving a high cumulative OCS burden, the questionnaire scores for 
those receiving a biologic were significantly better compared to participants not 
receiving a biologic only for the SAQ-global score. There were no significant 
difference between those receiving or not receiving biologics for the other scales 
(Table 4).   
Participants  not on biologic treatments but with a low cumulative OCS burden 
scored significantly better on the following questionnaires compared to participants 
not on biologics but with a high cumulative OCS burden: SAQ, EQ5D, EQ5D-VAS 
and the SAQ-global score (Table 4). Scores for the ACT and GSQ were not 
significantly different between the two groups.  
Table 4: Mean questionnaire scores for participants on/off a biologic drug and with 





































































Significant differences between: a-b (p = 0.014), c-d (p = 0.019), e-f (p = 0.023), g-h 
(p = 0.031), i-j (p = 0.037) 




This survey of the extra-pulmonary symptoms in patients with severe asthma 
showed that extra-pulmonary symptoms are common.  The median number of extra-
pulmonary symptoms reported per week was 21, but there is variability in the 
number of symptoms reported. Four patients reported zero symptoms per week and 
13 reported 45 or more symptoms per week.  
We examined to what extent pulmonary symptoms and extra-pulmonary symptoms 
contribute to HRQoL as measured by the SAQ. Extra-pulmonary symptoms and 
pulmonary symptoms were measured using the ACT and GSQ respectively. The 
amount of variation of HRQoL explained by these two different types of symptom 
was approximately the same for the SAQ whereas there was tendency for more 
variation of the SAQ-Global to be explained by the pulmonary symptoms.  These 
results show that extra-pulmonary symptoms should be considered an important 
contributor to quality of life in patients with severe asthma.  
 One way of evaluating patient reported outcomes using cross-sectional data is to 
identify to what extent they discriminate between different groups.  We investigated 
the ability of patient reported outcomes to distinguish between groups receiving 
different treatments.  Treatment and severity are confounded as patients who are 
more severe and therefore expected to have worse outcomes receive more 
treatment.  We found that, for patients not on biologics, those receiving low 
cumulative OCS had significantly better outcomes compared to those receiving high 
cumulative OCS on all scales except the ACT and GSQ. It is not possible to tell from 
this finding whether the difference is because of the side effects of OCS or because 
those on OCS are more severe and so have poorer quality of life.  However, for one 
comparison there is little confound: patients who were receiving high cumulative 
doses of OCS with and without biologics.  Both these groups comprise more severe 
patients, with the possibility that those receiving biologics are more severe than 
those not receiving biologics. We found that for these more severe patients there 
was a trend for patients to have improved quality of life if they were on biologics, but 
significance was found only for the SAQ-global.  
As biologics are reserved for people meeting strict severity criteria and therefore may 
be more severe than those not receiving biologics, our results are in the opposite 
direction of a confound between severity and treatment.  These data therefore 
provide preliminary cross-sectional evidence that biologics improve overall health 
outcomes, but to different degrees depending on the PRO.  Further longitudinal 
research is needed as our results also indicate that different PROs may be 
differentially sensitive to the benefits of biologics.  
Limitations 
 It is not possible to determine the cause of the extra-pulmonary symptoms with 
these data. Longitudinal data are needed to determine whether the significantly 
worse SAQ, EQ5D, EQ5D-VAS and the SAQ-global scores observed in the high 
cumulative OCS group is caused by the side effects associated with increased OCS 
exposure or the symptoms of severe asthma or both. Data were collected from a 
single site in the South West of England.  
Measures of personality type or co-morbid anxiety/depression were not recorded as 
part of this study and could not be included in the regression model. As such it was 
not possible to determine if one of these factors influenced the variation of HRQoL 
explained by pulmonary or extra-pulmonary symptoms. Evidence from elsewhere 
already suggests that patients with high levels of anxiety experience worse asthma 
symptoms (14, 15) and those with a greater number of comorbidities have a poorer 
response to omalizumab (16).  
Conclusions  
This study shows that both extra-pulmonary and respiratory specific symptoms are 
important contributors to disease specific HRQoL.  The impact of treatment on 
quality of life and extra-pulmonary symptoms should be taken into account when 
making treatment decisions.  
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